Biocon

BIOCON.NSApproved

Bengaluru, IndiaFounded 1978biocon.com

Founded in 1978 by Kiran Mazumdar-Shaw, Biocon has evolved from a garage startup into Asia's premier biotechnology enterprise with a focus on affordable healthcare solutions. The company operates through three key subsidiaries: Biocon Biologics (biosimilars), Biocon Pharma (generics), and Syngene (research services), serving patients in over 120 countries. Biocon has established itself as a pioneer in insulin manufacturing and biosimilar development, with multiple products approved by stringent regulatory authorities including FDA and EMA.

Market Cap

$6.6B

Founded

1978

Employees

10,000-12,000

Focus

Biotech

BIOCON.NS · Stock Price

USD 380.00+50.00 (+15.15%)

Historical price data

AI Company Overview

Technology Platform

Integrated biotechnology platform specializing in biosimilar development and manufacturing through advanced bioprocess engineering, fermentation technology, and end-to-end biologics production capabilities.

Pipeline Snapshot

23 drugs in pipeline, 7 in Phase 3

Drug	Indication	Stage
EQ001 + EQ001 Placebo	Coronavirus	Phase 3
Bmab 1000 + Prolia®	Postmenopausal Women With Osteoporosis	Phase 3
Itolizumab + EQ001 Placebo	Graft Versus Host Disease	Phase 3
PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab,...	HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients	Phase 3
Stelara + Bmab1200	Moderate to Severe Chronic Plaque Psoriasis	Phase 3

Funding History

Total raised: $10M

IPO$10MUndisclosedMar 15, 2004

Series AUndisclosedUndisclosedJun 15, 1994

FDA Approved Drugs

SERTRALINE HYDROCHLORIDEANDAJan 20, 2026

EVEROLIMUSANDAJan 9, 2026

AUKELSOBLASep 16, 2025

Opportunities

Significant growth potential from expanding biosimilar pipeline approvals in developed markets, increasing penetration in emerging markets, and potential IPO of Biocon Biologics subsidiary.

Novel biologics programs in immunology could provide high-value differentiated products.

Risk Factors

Regulatory approval delays for key biosimilar products, intense pricing competition in developed markets, and potential manufacturing quality issues.

Currency fluctuation and geopolitical tensions could impact international operations.

Competitive Landscape

Competes with global biosimilar leaders like Sandoz, Celltrion, and Samsung Bioepis, but differentiates through cost leadership from India manufacturing, proven regulatory track record, and strong emerging market presence. Faces increasing competition from large pharma entering biosimilars space.

Publications

Patents

Pipeline

FDA Approvals